Drug Search Results
More Filters [+]

Brequinar

Alternative Names: brequinar
Latest Update: 2024-04-24
Latest Update Note: PubMed Publication

Product Description

Brequinar is a synthetic quinolinecarboxylic acid analogue with antineoplastic properties. Brequinar inhibits the enzyme dihydroorotatedehydrogenase, thereby blocking de novo pyrimidine biosynthesis. This agent may also enhance the in vivo antitumor effect of antineoplastic agents such as 5-FU. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Brequinar)

Mechanisms of Action: DHODH Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Clear Creek Bio
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Brequinar

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: COVID-19|Acute Myeloid Leukemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CCBCRISIS04

P2

Terminated

COVID-19

2022-06-04

CRISIS2

P2

Completed

COVID-19

2021-04-28

CCB-01

P2

Terminated

Acute Myeloid Leukemia

2020-12-31

CRISIS

P2

Completed

COVID-19

2020-12-29

Recent News Events